{"DataElement":{"publicId":"6706642","version":"1","preferredName":"Population Group Pharmacokinetic Study Coagulation Factor IX Extended Half Life One-Stage Clotting Factor Assay","preferredDefinition":"A group of individuals united by a common factor (e.g., geographic location, ethnicity, disease, age, gender)_A study of the process by which a drug is absorbed, distributed, metabolized, and eliminated by the body._Coagulation factor IX (461 aa, ~52 kDa) is encoded by the human F9 gene. This protein plays a role in the intrinsic pathway of blood coagulation through the mediation of proteolysis that converts factor X into an active protease._The amount of time needed for a material to lose half of its physical, chemical, or biological activity._To increase in length or duration._A clotting factor assay where FVIII?deficient plasma is added to test plasma and the APTT reagent, mixed and incubated for 3?5 min. The mixture is then recalcified, and the coagulation time is recorded and compared to a standard curve.","longName":"Popu_Phar_Coag_Exte_Half_67328","context":"PhenX","contextVersion":"1","DataElementConcept":{"publicId":"6706640","version":"1","preferredName":"Population Group Pharmacokinetic Study Coagulation Factor IX Extended Half Life","preferredDefinition":"A group of individuals united by a common factor (e.g., geographic location, ethnicity, disease, age, gender)_A study of the process by which a drug is absorbed, distributed, metabolized, and eliminated by the body._Coagulation factor IX (461 aa, ~52 kDa) is encoded by the human F9 gene. This protein plays a role in the intrinsic pathway of blood coagulation through the mediation of proteolysis that converts factor X into an active protease._The amount of time needed for a material to lose half of its physical, chemical, or biological activity._To increase in length or duration.","longName":"Popu_Phar_Coag_Exte_Half","context":"PhenX","contextVersion":"1","ObjectClass":{"publicId":"6706636","version":"1","preferredName":"Population Group Pharmacokinetic Study","preferredDefinition":"A group of individuals united by a common factor (e.g., geographic location, ethnicity, disease, age, gender):A study of the process by which a drug is absorbed, distributed, metabolized, and eliminated by the body.","longName":"C17005:C49663","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Population Group","conceptCode":"C17005","definition":"A group of individuals united by a common factor (e.g., geographic location, ethnicity, disease, age, gender)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Pharmacokinetic Study","conceptCode":"C49663","definition":"A study of the process by which a drug is absorbed, distributed, metabolized, and eliminated by the body.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"871581F0-C744-1C0F-E053-F662850AAFE3","latestVersionIndicator":"Yes","beginDate":"2019-04-21","endDate":null,"createdBy":"PANH","dateCreated":"2019-04-21","modifiedBy":"ONEDATA","dateModified":"2019-04-21","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"Property":{"publicId":"6706630","version":"1","preferredName":"Coagulation Factor IX Extend Half Life","preferredDefinition":"Coagulation factor IX (461 aa, ~52 kDa) is encoded by the human F9 gene. This protein plays a role in the intrinsic pathway of blood coagulation through the mediation of proteolysis that converts factor X into an active protease.:To increase in length or duration.:The amount of time needed for a material to lose half of its physical, chemical, or biological activity.","longName":"C28482:C25270:C70916","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Coagulation Factor IX","conceptCode":"C28482","definition":"Coagulation factor IX (461 aa, ~52 kDa) is encoded by the human F9 gene. This protein plays a role in the intrinsic pathway of blood coagulation through the mediation of proteolysis that converts factor X into an active protease.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"2"},{"longName":"Extend","conceptCode":"C25270","definition":"To increase in length or duration.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Half Life","conceptCode":"C70916","definition":"The amount of time needed for a material to lose half of its physical, chemical, or biological activity.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"87158879-CB5F-1C0B-E053-F662850A3B41","latestVersionIndicator":"Yes","beginDate":"2019-04-21","endDate":null,"createdBy":"PANH","dateCreated":"2019-04-21","modifiedBy":"ONEDATA","dateModified":"2019-04-21","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ConceptualDomain":{"publicId":"2008557","version":"1","preferredName":"Lab Results","preferredDefinition":"the results of laboratory tests.","longName":"LAB_RESULTS","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B2CFBA7D-D009-7227-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-12-27","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-12-27","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"87164183-EE19-1BEF-E053-F662850AFD3E","latestVersionIndicator":"Yes","beginDate":"2019-04-21","endDate":null,"createdBy":"PANH","dateCreated":"2019-04-21","modifiedBy":"PANH","dateModified":"2019-08-02","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ValueDomain":{"publicId":"6732888","version":"1","preferredName":"One-Stage Clotting Factor Assay","preferredDefinition":"A clotting factor assay where FVIII?deficient plasma is added to test plasma and the APTT reagent, mixed and incubated for 3?5 min. The mixture is then recalcified, and the coagulation time is recorded and compared to a standard curve.","longName":"6732888v1.0","context":"PhenX","contextVersion":"1","type":"Non-enumerated","dataType":"NUMBER","minLength":null,"maxLength":null,"minValue":null,"maxValue":null,"decimalPlace":null,"PermissibleValues":[],"ConceptualDomain":{"publicId":"2008557","version":"1","preferredName":"Lab Results","preferredDefinition":"the results of laboratory tests.","longName":"LAB_RESULTS","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B2CFBA7D-D009-7227-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-12-27","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-12-27","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"RepresentationTerm":{"publicId":"6732887","version":"1","preferredName":"One-Stage Clotting Factor Assay","preferredDefinition":"A clotting factor assay where FVIII‐deficient plasma is added to test plasma and the APTT reagent, mixed and incubated for 3–5 min. The mixture is then recalcified, and the coagulation time is recorded and compared to a standard curve.","longName":"C159550","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"One-Stage Clotting Factor Assay","conceptCode":"C159550","definition":"A clotting factor assay where FVIII-deficient plasma is added to test plasma and the APTT reagent, mixed and incubated for 3-5 min. The mixture is then recalcified, and the coagulation time is recorded and compared to a standard curve.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":"NCI Thesaurus","workflowStatus":"RELEASED","registrationStatus":"Application","id":"876F43BC-40A9-5EB3-E053-F662850A4510","latestVersionIndicator":"Yes","beginDate":"2019-04-26","endDate":null,"createdBy":"PANH","dateCreated":"2019-04-26","modifiedBy":"ONEDATA","dateModified":"2019-04-26","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"876F43BC-40BA-5EB3-E053-F662850A4510","latestVersionIndicator":"Yes","beginDate":"2019-04-26","endDate":null,"createdBy":"PANH","dateCreated":"2019-04-26","modifiedBy":"PANH","dateModified":"2019-08-02","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ClassificationSchemes":[{"publicId":"2793652","version":"1","longName":"PhenX","context":"PhenX","ClassificationSchemeItems":[{"publicId":"6641385","version":"1","longName":"Hemophilia","context":"PhenX"}]}],"AlternateNames":[],"ReferenceDocuments":[{"name":"Data Element Population Group Pharmacokinetic Study Coagulation Factor IX Extended Half Life One-Stage Clotting Factor Assay does not have Preferred Question Text","type":"Preferred Question Text","description":"Data Element Population Group Pharmacokinetic Study Coagulation Factor IX Extended Half Life One-Stage Clotting Factor Assay does not have Preferred Question Text","url":null,"context":"PhenX"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Standard","id":"87164183-EE2C-1BEF-E053-F662850AFD3E","latestVersionIndicator":"Yes","beginDate":"2019-04-21","endDate":null,"createdBy":"PANH","dateCreated":"2019-04-21","modifiedBy":"PANH","dateModified":"2020-06-15","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"}}